Before the anti-cyclin D1 antibody was widely available as a powerful tool to help distinguish MCL from CLL by flow cytometry, CD23 status had been considered very useful in separating CLL from MCL, especially when CD23 is either moderately. This evidence concerns the gene FCER2 and B-cell chronic lymphocytic leukemia.